Rebecca Klar Senter
Affiliations: | Massachusetts Institute of Technology, Cambridge, MA, United States |
Google:
"Rebecca Senter"Mean distance: 13.26 (cluster 6) | S | N | B | C | P |
Parents
Sign in to add mentor| Jeffrey P. Conn | grad student | 2011-2015 | Vanderbilt |
| Mark F. Bear | post-doc | 2015- | MIT |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin X, Fisher NM, Dogra S, et al. (2022) Differential activity of mGlu allosteric modulators provides evidence for mGlu heterodimers at hippocampal Schaffer Collateral-CA1 synapses. The Journal of Biological Chemistry. 102458 |
| Stoppel DC, McCamphill PK, Senter RK, et al. (2021) mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence. Frontiers in Psychiatry. 12: 718953 |
| McCamphill PK, Stoppel LJ, Senter RK, et al. (2020) Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome. Science Translational Medicine. 12 |
| Gogliotti RG, Senter RK, Fisher NM, et al. (2017) mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Science Translational Medicine. 9 |
| Walker AG, Sheffler DJ, Lewis AS, et al. (2017) Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP, Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Stoppel LJ, Auerbach BD, Senter RK, et al. (2017) β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X. Cell Reports. 18: 2807-2814 |
| Senter RK, Ghoshal A, Walker AG, et al. (2016) The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Current Neuropharmacology. 14: 455-73 |